Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
UNITUXIN vs UNLOXCYT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dinutuximab is a chimeric monoclonal antibody that binds to the disialoganglioside GD2, which is overexpressed on neuroblastoma cells. Binding to GD2 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
UNLOXCYT (pexidartinib) is a small-molecule tyrosine kinase inhibitor that inhibits colony-stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring internal tandem duplication mutations. It also inhibits platelet-derived growth factor receptor alpha (PDGFRA) and beta (PDGFRB). Inhibition of CSF1R reduces the survival and function of tumor-associated macrophages, which play a role in tenosynovial giant cell tumor (TGCT) pathogenesis.
FDA: Treatment of pediatric patients with high-risk neuroblastoma in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin.,Off-label: None commonly documented.
UNLOXCYT is indicated for the treatment of adult patients with severe tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.,Off-label uses: None established.
1,500 mg/m² intravenously over 1 hour on days 1, 8, and 15 of each 28-day cycle.
2 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
Terminal half-life approximately 22.6 days (range 11.4–45.3 days) in pediatric patients; supports every-other-week dosing. Half-life is prolonged compared to adults due to slower clearance in children.
Terminal elimination half-life is 12 hours (range 10-14 hours); steady-state achieved in approximately 2 days.
Dinutuximab is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific CYP450 enzyme involvement.
Pexidartinib is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C8 and CYP2C19. It is also a substrate of P-glycoprotein (P-gp).
Unchanged drug: negligible renal excretion; metabolism and biliary/fecal elimination are the primary routes. Specific % not established; in clinical studies, <1% of dose recovered in urine as parent drug.
Primarily renal (70% unchanged), with 20% fecal via biliary elimination and 10% metabolized.
Approximately 99.7% bound to human serum proteins; primarily binds to albumin and beta-2-glycoprotein I.
98% bound to albumin.
Estimated Vdss approximately 4.5 L (not weight-normalized; corresponds to ~0.06 L/kg in a 70 kg adult) indicating limited extravascular distribution.
0.15 L/kg; indicates limited extravascular distribution, primarily in plasma volume.
Only intravenous administration; bioavailability 100% by IV route.
Oral: 85% (tablet); Intravenous: 100%.
No specific dose adjustment recommended; use caution in severe renal impairment (Cr Cl < 30 m L/min) due to limited data.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
No specific dose adjustment for Child-Pugh Class A or B; not studied in Child-Pugh Class C.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not recommended in moderate to severe hepatic impairment (Child-Pugh B or C) due to potential increased toxicity.
Weight-based dosing: for patients ≤ 30 kg, 1,500 mg/m²; safety and efficacy not established in pediatric patients < 18 years.
Safety and efficacy not established in pediatric patients younger than 18 years.
No specific dose adjustment; elderly patients may have increased risk of infusion-related reactions and renal impairment.
No specific dose adjustment beyond standard dosing. Monitor for increased toxicity in patients aged ≥65 years due to limited data.
No FDA black box warning exists for dinutuximab.
WARNING: HEPATOTOXICITY. UNLOXCYT can cause serious and potentially fatal liver injury. Monitor liver function tests prior to initiation and at regular intervals during treatment. Withhold, reduce, or permanently discontinue UNLOXCYT based on severity of hepatotoxicity. UNLOXCYT is available only through a restricted program called the UNLOXCYT REMS Program.
Severe neuropathic pain requiring opioid analgesia; premedicate with opioids.,Capillary leak syndrome, which may be life-threatening.,Hypotension, hypertension, and tachycardia; monitor vital signs.,Peripheral neuropathy including sensory and motor deficits.,Serious infections, including sepsis.,Reversible posterior leukoencephalopathy syndrome (RPLS).,Infusion-related reactions including anaphylaxis.
Hepatotoxicity: Monitor liver tests at baseline and periodically. Withhold, reduce dose, or discontinue based on severity.,Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of effective contraception during treatment and for 1 month after the final dose.,Risk of hemorrhage: Can cause serious bleeding. Monitor for signs of bleeding.,QTc prolongation: Monitor ECG in patients at risk of QT prolongation.
History of anaphylactic reactions to dinutuximab or any of its excipients.
None.
No specific food interactions are known. Maintain adequate hydration. Grapefruit products should not be avoided unless specified by other medications. Manage electrolyte imbalances as needed, but no dietary restrictions.
No specific food interactions reported. Maintain adequate oral hydration. Avoid concurrent use of nephrotoxic drugs (e.g., NSAIDs, aminoglycosides) unless necessary.
Unituxin (dinutuximab) is a monoclonal antibody (Ig G1) that can cross the placenta. Based on its mechanism of action (GD2-directed), it is expected to cause fetal harm. In animal studies, administration during organogenesis resulted in embryolethality and structural abnormalities. First trimester: Avoid exposure due to risk of teratogenesis. Second/Third trimester: Risk of fetal GD2-positive tissue destruction; may cause fetal neurotoxicity and autonomic dysfunction. Contraindicated in pregnancy.
No human data; animal studies show fetal harm at exposures below human dose; contraindicated in pregnancy; black box warning for fetal toxicity.
It is unknown whether dinutuximab is excreted in human milk. Human Ig G is present in colostrum and breast milk, but it is degraded in the infant's gastrointestinal tract. However, neonatal Fc receptors may allow absorption. M/P ratio is not available. Because of the potential for serious adverse reactions (e.g., severe neuropathic pain, cytopenias) in the breastfed infant, women should not breastfeed during treatment and for at least 6 months after the last dose.
Unknown if excreted in human milk; M/P ratio not available; advise against breastfeeding due to potential for serious adverse reactions.
No specific pharmacokinetic studies in pregnancy exist. Pregnancy-induced increases in plasma volume and Ig G catabolism may reduce drug exposure. However, due to high risk of fetal harm, dinutuximab should not be used in pregnancy. If unavoidable, consider therapeutic drug monitoring (if available) and adjust dose based on clinical response and toxicity, but no standard adjustment is established.
No established dose; contraindicated; if exposure occurs, discontinue drug and consult specialist.
Unituxin (dinutuximab) is a monoclonal antibody targeting GD2 ganglioside on neuroblastoma cells. Premedicate with antihistamines, acetaminophen, and IV fluids to reduce infusion reactions. Monitor for severe neuropathic pain, which may require opioid analgesics and dose interruption. Risk of capillary leak syndrome, hypotension, and hyponatremia; check vital signs and electrolytes frequently. Administer in a specialized oncology setting with resuscitation equipment available.
UNLOXCYT (lutetium Lu 177 vipivotide tetraxetan) is a radiolabeled PSMA-targeted therapy for PSMA-positive metastatic castration-resistant prostate cancer. Prehydrate and administer concomitant amino acid solution to reduce renal uptake. Monitor for myelosuppression, xerostomia, and nephrotoxicity. Ensure adequate oral hydration post-infusion. Use strict radiation safety precautions; patient urine is radioactive for up to 30 days. Discontinue concomitant nephrotoxic drugs if possible.
Unituxin is given intravenously over 10-20 hours. You will receive medicines before infusion to reduce side effects.,Common side effects include severe pain, fever, low blood pressure, and allergic reactions. Report any chest tightness, difficulty breathing, or severe abdominal pain immediately.,You may experience nerve pain; this can be managed with pain medications. Do not drive if you are taking opioid pain relievers.,Drink plenty of fluids unless instructed otherwise. Your urine output will be monitored.,This drug can cause fluid retention; report rapid weight gain or swelling of legs or feet.,Avoid live vaccines while on this therapy and for at least 6 months after treatment.,Do not become pregnant or father a child during treatment; use effective contraception.
This drug is radioactive; you will be isolated for a few hours after infusion to protect others.,Drink plenty of water for at least 2 days after treatment to help eliminate the drug from your body.,Use a separate toilet and flush twice with the lid down for 1 week. Wash hands thoroughly.,Avoid close contact (within 1 meter) with pregnant women, children, and infants for 1 week.,Sleep in a separate bed and maintain distance from others for several days.,Possible side effects include dry mouth, nausea, low blood counts, and kidney issues.,Use effective contraception during treatment and for 14 weeks after the last dose.,Do not breastfeed during and for 5 months after treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about UNITUXIN vs UNLOXCYT, answered by our medical review team.
UNITUXIN is a Monoclonal Antibody (CD20-directed) that works by Dinutuximab is a chimeric monoclonal antibody that binds to the disialoganglioside GD2, which is overexpressed on neuroblastoma cells. Binding to GD2 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).. UNLOXCYT is a Monoclonal Antibody (CD20-directed) that works by UNLOXCYT (pexidartinib) is a small-molecule tyrosine kinase inhibitor that inhibits colony-stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring internal tandem duplication mutations. It also inhibits platelet-derived growth factor receptor alpha (PDGFRA) and beta (PDGFRB). Inhibition of CSF1R reduces the survival and function of tumor-associated macrophages, which play a role in tenosynovial giant cell tumor (TGCT) pathogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between UNITUXIN and UNLOXCYT depend on the specific clinical indication. These are both Monoclonal Antibody (CD20-directed) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of UNITUXIN is: 1,500 mg/m² intravenously over 1 hour on days 1, 8, and 15 of each 28-day cycle.. The standard adult dose of UNLOXCYT is: 2 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between UNITUXIN and UNLOXCYT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. UNITUXIN is classified as Category C. Unituxin (dinutuximab) is a monoclonal antibody (IgG1) that can cross the placenta. Based on its mechanism of action (GD2-directed), it is expected to cause fetal harm. In animal s. UNLOXCYT is classified as Category C. No human data; animal studies show fetal harm at exposures below human dose; contraindicated in pregnancy; black box warning for fetal toxicity.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.